Early-onset and Late-onset Sporadic Alzheimer's Disease (AD)

Assistance Publique Hopitaux De Marseille240 enrolled

Overview

Alzheimer's disease (AD) is usually associated with aging, age being the principal identified risk factor. However, younger subjects also develop AD and the prevalence of early onset AD is unknown. It is estimated that about 30 000 subjects develop symptoms of AD before the age of 65 in France. There is evidence that early onset AD differs from AD in older patients. In particular, clinical and neuroimaging studies suggest early involvement of neocortical brain regions and their functions in early onset AD, while mediotemporal areas and memory might be more involved in late onset AD. These differences could partly explain the atypical clinical and imaging features of younger patients, the diagnostic difficulties in these patients and the specific problems related to medical care of this age group. The present study uses a multidisciplinary approach with longitudinal followup in order to establish the impact of age on the clinical and neuroimaging picture of sporadic AD in a multicentric setting. Another aim of the project is to describe for each age group, and in particular for the younger patient group, the functional impact of disability in everyday life on both, patients and caregivers.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

240

Conditions

Alzheimer's Disease

Interventions

Clinic and neuropsychologic evaluationBIOLOGICAL

evaluation at the inclusion and 18 months after

MRIRADIATION

intervention at the inclusion and 18 months after

PETPROCEDURE

18-FDG (18-fluoro-2-deoxyglucose)PET imaging of the brain at the inclusion and 18 months after.

Apolipoprotein E genotypingBIOLOGICAL

genotyping at the inclusion

Study of cerebrospinal fluidBIOLOGICAL

intervention at the inclusion

Eligibility

Sex: ALLMin age: 45 YearsMax age: 90 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Arm Alzheimer Disease : first symptoms from 1 to 5 years before the inclusion, Clinical Dementia Rating = 1, efficient contraception for women * Arm Control : efficient contraception for women Exclusion Criteria: * Important general disease : diabetes, neoplasia, alcoholism * First symptoms less than 1 year or more than 5 years before the inclusion * Pregnancy, breast feeding

Outcomes

Primary Outcomes

to establish the impact of age on the clinical and neuroimaging picture of sporadic Alzheimer Disease in a multicentric setting.

Time frame: 3 years

Secondary Outcomes

to describe for each age group, and in particular for the younger patient group, the functional impact of disability in everyday life on both, patients and caregivers.